Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - scPharmaceuticals Inc. | d435316dex101.htm |
| EX-21.1 - EX-21.1 - scPharmaceuticals Inc. | d435316dex211.htm |
| EX-10.7 - EX-10.7 - scPharmaceuticals Inc. | d435316dex107.htm |
| EX-10.6 - EX-10.6 - scPharmaceuticals Inc. | d435316dex106.htm |
| EX-10.5 - EX-10.5 - scPharmaceuticals Inc. | d435316dex105.htm |
| EX-4.1 - EX-4.1 - scPharmaceuticals Inc. | d435316dex41.htm |
| EX-3.4 - EX-3.4 - scPharmaceuticals Inc. | d435316dex34.htm |
| EX-3.1 - EX-3.1 - scPharmaceuticals Inc. | d435316dex31.htm |
| S-1 - S-1 - scPharmaceuticals Inc. | d435316ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Registration Statement on Form S-1 of scPharmaceuticals, Inc. of our report dated April 17, 2017, except for the Net Loss per Share disclosures included in Note 3 as to which the date is August 30, 2017, relating to the financial statements of scPharmaceuticals, Inc., appearing in the Prospectus, which is part of this Registration Statement.
We also consent to the reference to our firm under the heading “Experts”.
/s/ RSM US LLP
Boston, Massachusetts
October 23, 2017